Clinical trials: Atomoxetine Hydrochloride
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Role of the Noradrenergic System in the Regulation of Learning Dynamics, No Disease or Condition is Being Studied
Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)
Administration of low-dose selective noradrenaline reuptake inhibitor (sNRI) (e.g. atomoxetine) to healthy subjects is a validated model of increasing cortical noradrenaline levels which, combined with computational modelling of…
- Trial name
- NOISYXETINE (NCT07239791)
- Testing
- Atomoxetine
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Attention Deficit Hyperactivity Disorder
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder
- Trial name
- NCT00191880
- Testing
- atomoxetine
- Where
- 8 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Addiction
Cognitive Effects of Atomoxetine in Humans: Genetic Moderators
The overall goal of this study is to determine if atomoxetine treatment improves selective cognitive functions in abstinent cocaine users, compared to healthy controls.
- Trial name
- NCT01498549
- Testing
- Atomoxetine, Sugar Pill
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Memory Disorders, Multiple Sclerosis
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
The purpose of this crossover trial is to investigate whether atomoxetine (versus placebo) improves memory function in persons with memory deficits due to multiple sclerosis.
- Trial name
- NCT03091400
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Traumatic Brain INjury
Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)
Atomoxetine is the only medication that is currently approved by the FDA for the treatment of attention deficit hyperactivity disorder in adults.
- Trial name
- NCT00702364
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Craig Hospital
Generalized Social Phobia
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder
The purpose of this study is to determine the effectiveness and tolerability of atomoxetine (Strattera) in adult patients with generalized social anxiety disorder (an anxiety disorder characterized by a fear of interpersonal…
- Trial name
- NCT00260533
- Testing
- atomoxetine
- Volunteers
- 27 people
- Sponsor
- University of California, San Diego
Parkinson's Disease, Idiopathic
TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease
Gait and balance problems are a significant source of disability in patients with Parkinson disease. Physical therapy remains one of the main treatments.
- Trial name
- TAME-PD (NCT02879136)
- Testing
- Methylphenidate, Physical Therapy, Atomoxetine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Hubert Fernandez
Vasovagal Syncope
Study of Atomoxetine in the Prevention of Vasovagal Syncope
Project rationale: Vasovagal syncope (VVS) affects up to 50% of people, and recurrent syncope markedly reduces quality of life. We recently reported that it is frequently associated with injury and not surprisingly with clinical…
- Trial name
- POST7 (NCT05159687)
- Testing
- Atomoxetine Hydrochloride
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- University of Calgary
Attention Deficit Hyperactivity Disorder
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Atomoxetine versus placebo in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00191295
- Testing
- Atomoxetine
- Where
- 24 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
ADHD, Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse
- Trial name
- NCT00190957
- Testing
- Atomoxetine
- Where
- 15 sites in United States, Canada
- Volunteers
- 140 people
- Sponsor
- Eli Lilly and Company
Executive Dysfunction
Effects of Atx and Oros-mph on Executive Functions
The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse…
- Trial name
- NCT02352051
- Testing
- Atomoxetine, methylphenidate
- Volunteers
- 43 people
- Sponsor
- TC Erciyes University
OSA
Continuation Protocol for Obstructive Sleep Apnea (OSA)
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA).
- Trial name
- NCT06566820
- Testing
- Aroxybutynin and Atomoxetine
- Where
- 99 sites in United States, Canada
- Volunteers
- 1,280 people, healthy volunteers welcome
- Sponsor
- Apnimed
Attention Deficit Hyperactivity Disorder, Behavior Hyperactive
Attention Deficit Hyperactivity Disorder
The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD…
- Conditions
- Attention Deficit Hyperactivity Disorder, Behavior Hyperactive, Behavior Disorders
- Trial name
- ADA (NCT06232226)
- Testing
- Patients suffering from the co-occurrence of ADHD and addiction(s)
- Where
- 3 sites in France
- Volunteers
- 80 people
- Sponsor
- Nantes University Hospital
Attention Deficit Hyperactivity Disorder
Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the change in neuropsychological status from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with ADHD.
- Trial name
- NCT00216918
- Testing
- Atomoxetine Hydrochloride
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Memory Disorders
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit…
- Conditions
- Schizophrenia, Memory Disorders, Cognition Disorders
- Trial name
- Atomoxetine (NCT00548327)
- Testing
- Atomoxetine, Functional magnetic resonance imaging, Neuropsychological Testing
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder, Reading Disorder
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with…
- Trial name
- NCT00191906
- Testing
- Atomoxetine Hydrochloride
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Tourette Syndrome
Atomoxetine in Patients With Tourette's Syndrome
The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.
- Trial name
- ATO-TS (NCT04354103)
- Testing
- Atomoxetine
- Where
- 3 sites in France
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder
- Trial name
- NCT00190879
- Testing
- Atomoxetine hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company